JHLT OpenPub Date : 2026-02-01Epub Date: 2025-10-29DOI: 10.1016/j.jhlto.2025.100422
Benjamin N. French MD , Anudeep S. Nakirikanti MD , Ian Kusher BS , Kris Wittersheim RN, MSN, APRN-BC , J. David Vega MD , Mani Daneshmand MD , Divya Gupta MD
{"title":"Left ventricular assist device implantation in advanced kidney disease","authors":"Benjamin N. French MD , Anudeep S. Nakirikanti MD , Ian Kusher BS , Kris Wittersheim RN, MSN, APRN-BC , J. David Vega MD , Mani Daneshmand MD , Divya Gupta MD","doi":"10.1016/j.jhlto.2025.100422","DOIUrl":"10.1016/j.jhlto.2025.100422","url":null,"abstract":"<div><h3>Background</h3><div>Advanced chronic kidney disease (CKD) is often considered a contraindication to left ventricular assist device (LVAD) implantation, yet limited data exist on outcomes in the era of the HeartMate 3 device.</div></div><div><h3>Methods</h3><div>We retrospectively reviewed 193 patients who underwent HeartMate 3 LVAD implantation at a tertiary care academic medical center between July 2016 and July 2023. Patients were stratified by preoperative estimated glomerular filtration rate (eGFR) ≥30 mL/min/1.73 m² (control, <em>n</em> = 154) vs <30 (advanced kidney disease, <em>n</em> = 39). Outcomes included survival and the need for renal replacement therapy (RRT).</div></div><div><h3>Results</h3><div>At 30 days post-implantation, survival was lower in advanced kidney disease patients compared with controls (84.6% vs 94.2%, <em>p</em> = 0.04). However, survival at 1 year (79.5% vs 79.9%, <em>p</em> = 0.87) and 2 years (73.9% vs 68.7%, <em>p</em> = 0.60) did not differ significantly. Post-implantation RRT was required in 30.3% of advanced kidney disease patients and 18.2% of controls (<em>p</em> = 0.18).</div></div><div><h3>Conclusions</h3><div>Although early postoperative mortality is higher, patients with advanced CKD undergoing HeartMate 3 LVAD implantation achieve comparable 1- and 2-year survival to controls. These findings suggest LVAD implantation may be a reasonable option in carefully selected patients with advanced kidney disease.</div></div>","PeriodicalId":100741,"journal":{"name":"JHLT Open","volume":"11 ","pages":"Article 100422"},"PeriodicalIF":0.0,"publicationDate":"2026-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145521156","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Histidine-rich glycoprotein ameliorated lung ischemia-reperfusion injury in a mouse model","authors":"Yujiro Kubo MD, PhD , Seiichiro Sugimoto MD, PhD , Daiki Ousaka PhD , Dengli Wang PhD , Toshiaki Ohara MD, PhD , Toshio Shiotani MD, PhD , Shin Tanaka MD, PhD , Ken Suzawa MD, PhD , Kazuhiko Shien MD, PhD , Kentaroh Miyoshi MD, PhD , Mikio Okazaki MD, PhD , Yasuyuki Hosono MD, PhD , Akihiro Matsukawa MD, PhD , Shinichi Toyooka MD, PhD","doi":"10.1016/j.jhlto.2025.100453","DOIUrl":"10.1016/j.jhlto.2025.100453","url":null,"abstract":"<div><h3>Background</h3><div>Histidine-rich glycoprotein (HRG) is a multifunctional plasma glycoprotein involved in the regulation of various biological processes. Decreased plasma levels of HRG at 72 h after lung transplantation have been shown to be associated with severe primary graft dysfunction and poor transplant outcomes. In this study, we examined the effect of HRG supplementation on lung ischemia-reperfusion injury (IRI) in mice.</div></div><div><h3>Methods</h3><div>The experimental mice were divided into a Sham group and three IRI groups (n=5 each) that received phosphate-buffered saline, human serum albumin, or HRG (HRG/IRI group), respectively. The lung function, lung injury, neutrophil infiltration, cellular apoptosis, inflammatory mediators, neutrophil extracellular traps (NETs), translocation status of high-mobility group box 1 (HMGB1), and hemolytic products in the injured tissue/plasma were compared among the groups.</div></div><div><h3>Results</h3><div>The HRG/IRI group showed significantly improved oxygenation capacity and a reduced severity of lung injury as compared with the other IRI groups. The HRG/IRI group also showed significantly less severe tissue inflammation in the reperfused lung, including a lower level of neutrophil infiltration, apoptotic cells, and neutrophil-associated inflammatory mediators than the other IRI groups. Moreover, formation of NETs and HMGB1 translocation were significantly suppressed in the HRG/IRI group as compared with the other IRI groups. A significantly greater degree of scavenging of hemolytic products was observed in the HRG/IRI group than the other IRI groups.</div></div><div><h3>Conclusion</h3><div>HRG supplementation ameliorated lung IRI in mice by suppressing inflammatory responses triggered by neutrophil-associated factors, including formation of NETs, HMGB1 translocation, and accumulation of hemolytic products.</div></div>","PeriodicalId":100741,"journal":{"name":"JHLT Open","volume":"11 ","pages":"Article 100453"},"PeriodicalIF":0.0,"publicationDate":"2026-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145736370","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Parasitic diseases in heart transplantation: challenges of Toxoplasmosis and Chagas Disease","authors":"Alexandre Mestre Tejo MD , Silvia Vidal Campos PhD","doi":"10.1016/j.jhlto.2025.100450","DOIUrl":"10.1016/j.jhlto.2025.100450","url":null,"abstract":"<div><div>Parasitic diseases have always caused a significant burden in endemic countries. However, due to globalization and immigration, more cases are emerging in non-endemic regions, leading to a growing incidence in solid organ transplantation. These immunocompromised patients, such diseases, have the potential to reactivate and cause severe disease and graft damage, often leading to death. Two specific parasites play a special role in the heart transplant scenario: <em>Trypanosoma cruzi</em>, responsible for Chagas disease, and T<em>oxoplasma gondii</em>, for Toxoplasmosis. In endemic countries, Chagas disease is not only one of the main indications for a heart transplant, but also responsible for several episodes of reactivation after transplantation, requiring careful surveillance for preemptive treatment. <em>T. gondii</em> has the potential to reactivate in immunocompromised hosts, leading to myocarditis and/or disseminated disease, often fatal. Prophylaxis is safe and effective to prevent reactivation. This review aims to summarize the most important aspects of Chagas disease and Toxoplasmosis in the heart transplant setting, with emphasis on pre-transplant screening, prophylaxis, and monitoring.</div></div>","PeriodicalId":100741,"journal":{"name":"JHLT Open","volume":"11 ","pages":"Article 100450"},"PeriodicalIF":0.0,"publicationDate":"2026-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145839590","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
JHLT OpenPub Date : 2026-02-01Epub Date: 2025-11-25DOI: 10.1016/j.jhlto.2025.100447
Charlotte J. Van Edom MD , Walter Droogné MD , Steven Jacobs MD, PhD , Marc Jacquemin MD PhD , Christine Van Laer PhD , Joeri Van Puyvelde MD, PhD , Dirk Vlasselaers MD, PhD , Katrien Vandersmissen , Thomas Vanassche MD, PhD , Bart Meyns MD, PhD
{"title":"Thrombin generation in HeartMate 3 patients on apixaban and vitamin K antagonists: Variability limits clinical applicability","authors":"Charlotte J. Van Edom MD , Walter Droogné MD , Steven Jacobs MD, PhD , Marc Jacquemin MD PhD , Christine Van Laer PhD , Joeri Van Puyvelde MD, PhD , Dirk Vlasselaers MD, PhD , Katrien Vandersmissen , Thomas Vanassche MD, PhD , Bart Meyns MD, PhD","doi":"10.1016/j.jhlto.2025.100447","DOIUrl":"10.1016/j.jhlto.2025.100447","url":null,"abstract":"<div><div>Apixaban is increasingly replacing vitamin K antagonists (VKAs) during HeartMate 3 (HM3) left ventricular assist device support, but its pharmacodynamics in this setting remain poorly understood. Thrombin generation assays (TGAs) allow for comparison of the overall anticoagulant effect. TGAs were performed in 24 HM3 patients on apixaban, dosed to maintain trough levels >50 ng/liter, and 6 on VKAs with target INR 2 to 3, without recent coagulopathy. Apixaban was associated with shorter lag time and time-to-peak thrombin generation, indicating faster coagulation initiation. Endogenous thrombin potential (ETP) was higher with apixaban, but both peak thrombin and ETP showed high interindividual variability. Apixaban levels correlated modestly with initiation parameters, but not with ETP or peak thrombin. These findings demonstrate pharmacodynamic differences between apixaban and VKAs, but also highlight substantial variability and limited clinical applicability for apixaban dose titration. TGAs should therefore be regarded as research tools rather than monitoring assays in this setting.</div></div>","PeriodicalId":100741,"journal":{"name":"JHLT Open","volume":"11 ","pages":"Article 100447"},"PeriodicalIF":0.0,"publicationDate":"2026-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145839582","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
JHLT OpenPub Date : 2026-02-01Epub Date: 2025-12-19DOI: 10.1016/j.jhlto.2025.100469
Marniker Wijesinha PhD , Michael Terrin MD , Si Pham MD , Aldo Iacono MD
{"title":"Survival improvement with sirolimus plus tacrolimus immunosuppression for treatment of bronchiolitis obliterans syndrome after lung transplantation","authors":"Marniker Wijesinha PhD , Michael Terrin MD , Si Pham MD , Aldo Iacono MD","doi":"10.1016/j.jhlto.2025.100469","DOIUrl":"10.1016/j.jhlto.2025.100469","url":null,"abstract":"<div><h3>Background</h3><div>Chronic rejection, usually manifesting as bronchiolitis obliterans syndrome (BOS), is the leading cause of death among lung transplant patients. Prior lung transplant studies showed higher overall survival and lower BOS incidence associated with sirolimus (SIR) + tacrolimus (TAC) versus conventional mycophenolate mofetil (MMF) + TAC immunosuppression. However, after BOS occurs, it is unknown how immunosuppressive drugs may be linked to survival.</div></div><div><h3>Methods</h3><div>This study included U.S. lung transplant recipients in the Lung Allocation Score era (starting May 2005), with a BOS diagnosis documented from 2006 to 2020, in the Scientific Registry of Transplant Recipients dataset. Survival was compared between patients receiving MMF+TAC, SIR+TAC, or SIR+TAC+MMF/azathioprine (SIR+TAC+MMF/AZA) after BOS onset, using multivariable adjusted Cox regression and Inverse Probability of Treatment Weighting (IPTW)-adjusted Kaplan-Meier estimates.</div></div><div><h3>Results</h3><div>SIR+TAC+MMF/AZA (HR=0.60, p=0.03, n=47) and SIR+TAC (HR=0.67, p=0.04, n=95) were associated with better survival than MMF+TAC (n=1012); each group contained patients from >15 centers. IPTW-adjusted survival probabilities for SIR+TAC+MMF/AZA, SIR+TAC, and MMF+TAC, respectively, were, 1-year: 91%, 84%, 80% and 5-year: 50%, 58%, 42%. Within severely affected BOS patients (BOS Grade 3, or FEV<sub>1</sub> decrease ≥30%/year, or FEV<sub>1</sub><25% of predicted at BOS documentation), SIR+TAC+MMF/AZA (HR=0.32, p=0.03) and SIR+TAC (HR=0.50, p=0.05) had larger survival advantages over MMF+TAC; the respective survival probabilities were, 1-year: 91%, 70%, 59%, and 5-year: 41%, 35%, 20%.</div></div><div><h3>Conclusions</h3><div>Sirolimus + tacrolimus immunosuppression may improve survival in BOS patients, especially severely affected patients with BOS Grade 3, or rapidly declining or low FEV<sub>1</sub>. Adding MMF or azathioprine to this combination may further increase short-term survival.</div></div>","PeriodicalId":100741,"journal":{"name":"JHLT Open","volume":"11 ","pages":"Article 100469"},"PeriodicalIF":0.0,"publicationDate":"2026-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146026158","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
JHLT OpenPub Date : 2026-02-01Epub Date: 2026-01-02DOI: 10.1016/j.jhlto.2025.100479
Joshua A. Rushakoff MD, MPP , Adam D. DeVore MD, MHS , Richa Agarwal MD , Joseph B. Lerman MD , Karen Flores Rosario MD , Jeffrey Keenan MD , Jacob N. Schroder MD , Carmelo A. Milano MD , Chetan B. Patel MD
{"title":"Listing patterns at the highest volume heart transplant centers: Multiple roads to transplant","authors":"Joshua A. Rushakoff MD, MPP , Adam D. DeVore MD, MHS , Richa Agarwal MD , Joseph B. Lerman MD , Karen Flores Rosario MD , Jeffrey Keenan MD , Jacob N. Schroder MD , Carmelo A. Milano MD , Chetan B. Patel MD","doi":"10.1016/j.jhlto.2025.100479","DOIUrl":"10.1016/j.jhlto.2025.100479","url":null,"abstract":"<div><div>The current heart transplantation (HT) allocation system added additional progressive statuses to differentiate the highest risk patients and decrease waitlist mortality. We analyzed United Network for Organ Sharing thoracic organ data (10/18/2018-6/30/2025) to assess listing practices at the 10 highest volume centers (5,466 total HT). We found variation in the final waitlist status across these centers (status 1 3.6% to 16.4%; status 6 0.5%-14.5%). Further, some centers had more even distributions across final status, while others had dominant status 2 patterns. As continuous distribution allocation is considered for HT, we feel it is critical to consider the practice patterns of these highest-volume centers. Notably, HT candidates may not conform to a prescribed course through escalating statuses.</div></div>","PeriodicalId":100741,"journal":{"name":"JHLT Open","volume":"11 ","pages":"Article 100479"},"PeriodicalIF":0.0,"publicationDate":"2026-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146026192","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
JHLT OpenPub Date : 2026-02-01Epub Date: 2025-12-18DOI: 10.1016/j.jhlto.2025.100468
Shoaib Ahmad MD , Curt Bay PhD , Michael D. Nailor PharmD , Christine Pham PharmD , Ross M. Bremner MD, PhD , Ali Imran Saeed MD , Kellie J. Goodlet PharmD , Sofya Tokman MD
{"title":"Kaposi sarcoma in lung transplant recipients with public health service increased-risk donors: A retrospective cohort study and review of the literature","authors":"Shoaib Ahmad MD , Curt Bay PhD , Michael D. Nailor PharmD , Christine Pham PharmD , Ross M. Bremner MD, PhD , Ali Imran Saeed MD , Kellie J. Goodlet PharmD , Sofya Tokman MD","doi":"10.1016/j.jhlto.2025.100468","DOIUrl":"10.1016/j.jhlto.2025.100468","url":null,"abstract":"<div><h3>Purpose</h3><div>To investigate the relationship between Public Health Service (PHS) increased-risk donors and post-lung transplant (LT) Kaposi sarcoma (KS).</div></div><div><h3>Methods</h3><div>This retrospective cohort study included LT recipients (April 1, 2019-April 1, 2024) who had PHS increased-risk donors at our institution. Data were abstracted from UNOS and electronic medical records. Published post-LT KS cases were also reviewed. Descriptive statistics and Kaplan–Meier estimates were used.</div></div><div><h3>Results</h3><div>Of 467 LT recipients, 90 (23.9%) had PHS increased-risk donors, including 13 [14.4%] men who have sex with men (MSM). Four of these 13 (30.8%) recipients developed KS (median time to diagnosis, 365 days [IQR 276–502]). Basiliximab was the most common induction agent; all 4 patients were on standard 3-drug immunosuppression. All 4 recipients had pulmonary KS without extrapulmonary involvement and positive human herpes virus 8 (HHV-8) immunohistochemistry results. Pulmonary nodules were incidentally noted on chest CT in 3 asymptomatic patients; 1 patient presented with dyspnea and central airway obstruction. Immunosuppression was reduced and mTOR inhibitors were initiated for all 4 patients; 1 patient underwent stenting of the left main bronchus and radiation, and 1 was treated with liposomal doxorubicin. Three recipients improved, and 1 is awaiting follow-up imaging (median follow-up, 276 days [IQR 177–433]). In our data pooled with 15 published cases, mean survival time was lower in patients with disseminated KS (182 vs. 563 days, p=0.011).</div></div><div><h3>Conclusion</h3><div>LT recipients with MSM donors may be at an increased risk for post-LT KS from donor-derived HHV-8. Larger, more definitive, multicenter studies are needed.</div></div>","PeriodicalId":100741,"journal":{"name":"JHLT Open","volume":"11 ","pages":"Article 100468"},"PeriodicalIF":0.0,"publicationDate":"2026-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145975967","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
JHLT OpenPub Date : 2026-02-01Epub Date: 2025-11-14DOI: 10.1016/j.jhlto.2025.100437
Erlon de Avila Carvalho MD, PhD , Bruna Carregal Coelho MSc , Rachid Eduardo Noleto da Nobrega Oliveira MD, MS , Lucas Monteiro Delgado MSc , Felipe S. Passos MD , Tulio Caldonazo MD , Marcelo Cypel MD, PhD
{"title":"Veno-venous versus Veno-arterial extracorporeal membrane oxygenation for the management of primary graft dysfunction following lung transplantation: A systematic review and meta-analysis","authors":"Erlon de Avila Carvalho MD, PhD , Bruna Carregal Coelho MSc , Rachid Eduardo Noleto da Nobrega Oliveira MD, MS , Lucas Monteiro Delgado MSc , Felipe S. Passos MD , Tulio Caldonazo MD , Marcelo Cypel MD, PhD","doi":"10.1016/j.jhlto.2025.100437","DOIUrl":"10.1016/j.jhlto.2025.100437","url":null,"abstract":"<div><h3>Background</h3><div>Primary graft dysfunction (PGD) is the leading cause of early morbidity and mortality after lung transplantation. In its severe forms, extracorporeal membrane oxygenation (ECMO) may be required. However, there is no consensus on whether venovenous (VV) or venoarterial (VA) ECMO modality provides superior outcomes. The objective of this meta-analysis is to compare the use of VV-ECMO versus VA-ECMO in the management of grade 3 PGD after lung transplantation.</div></div><div><h3>Methods</h3><div>Three databases were assessed. Primary outcome was overall survival (OS). Secondary outcomes included cerebrovascular complications, incidence of pneumonia, reintubation, acute kidney injury, ICU length of stay and ECMO duration. Hazard ratios (HR), odds ratios (OR) and mean difference (MD) with 95% confidence intervals (CIs) were calculated. Reconstruction of time-to-event data and sensitivity analyses were performed for the primary endpoint.</div></div><div><h3>Results</h3><div>Four studies including 210 patients (VV-ECMO: 142; VA-ECMO: 68) were analyzed. VV-ECMO was associated with improved early survival (HR 0.41; 95%CI 0.22 to 0.76; p=0.005) within the first 2 months after transplantation, although no significant difference was observed in long-term survival (HR 0.72; 95%CI 0.46 to 1.15; p=0.168). Cerebrovascular complications occurred significantly more often in the VA-ECMO group (OR 18.33; 95%CI 3.62 to 92.81; p=0.0004), while no significant differences were found in pneumonia, reintubation, acute renal failure, ICU length of stay, or ECMO duration.</div></div><div><h3>Conclusion</h3><div>VV-ECMO appears to be associated with better short-term survival and fewer neurological complications compared to VA-ECMO in patients with grade 3 PGD after lung transplantation.</div></div>","PeriodicalId":100741,"journal":{"name":"JHLT Open","volume":"11 ","pages":"Article 100437"},"PeriodicalIF":0.0,"publicationDate":"2026-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145684707","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
JHLT OpenPub Date : 2026-02-01Epub Date: 2025-12-04DOI: 10.1016/j.jhlto.2025.100458
Dieuwertje Ruigrok MD, PhD , Lucie E. Boersma MD , Jon Admiraal MD , Ares M. Rasoul MD , Nuray Kusadasi MD, PhD , Sue A. Braithwaite MD , Linda M. de Heer MD, PhD , Bart Luijk MD, PhD , Rob Schönwetter MD , Marco C. Post MD, PhD
{"title":"Venous thromboembolism in lung transplant recipients: timing and clinical impact, a 10-year cohort analysis","authors":"Dieuwertje Ruigrok MD, PhD , Lucie E. Boersma MD , Jon Admiraal MD , Ares M. Rasoul MD , Nuray Kusadasi MD, PhD , Sue A. Braithwaite MD , Linda M. de Heer MD, PhD , Bart Luijk MD, PhD , Rob Schönwetter MD , Marco C. Post MD, PhD","doi":"10.1016/j.jhlto.2025.100458","DOIUrl":"10.1016/j.jhlto.2025.100458","url":null,"abstract":"<div><h3>Introduction</h3><div>The burden of venous thromboembolism (VTE) in lung transplant (LTx) recipients is not fully elucidated despite its frequent occurrence. We report the incidence of VTE and characteristics of VTE in a large LTx cohort, assess severity using risk stratification algorithms, and explore associations with graft survival and chronic lung allograft dysfunction (CLAD).</div></div><div><h3>Methods</h3><div>A retrospective cohort analysis was performed on LTx recipients transplanted between July 2012 and August 2022 in our center. Primary outcome was incidence of VTE. Three groups were compared as follows: patients with early VTE (i.e<em>.,</em> within the first 6 months after LTx), late VTE (i.e<em>.,</em> beyond the first 6 months after LTx), and no VTE.</div></div><div><h3>Results</h3><div>About 94/286 patients (33%) were diagnosed with VTE (median follow-up of 4.3 years): 67/94 (71%) early VTE and 27/94 (29%) late VTE. 66/94 (70%) of VTE events were pulmonary embolism (PE). In the early VTE group, none of the PE cases were classified as intermediate-high risk PE and 1 patient had high-risk (fatal) PE. Graft survival was not different between groups; median CLAD-free survival was shorter in patients with late VTE (6.2 years) compared to patients without VTE during follow-up (9.8 years) (<em>p</em> = 0.044).</div></div><div><h3>Conclusions</h3><div>Thirty-three percent of LTx recipients developed VTE, 71% within the first 6 months after LTx. Seventy percent of cases were acute PE, but fatal or severe nonfatal PE were rare. No effect of VTE on graft survival was seen; CLAD-free survival was shorter in patients with late VTE compared to patients without VTE.</div></div>","PeriodicalId":100741,"journal":{"name":"JHLT Open","volume":"11 ","pages":"Article 100458"},"PeriodicalIF":0.0,"publicationDate":"2026-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145790211","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
JHLT OpenPub Date : 2026-02-01Epub Date: 2025-10-10DOI: 10.1016/j.jhlto.2025.100404
Ana Maria Bicudo Diniz MD , Adriana Loricchio Veiga MD , Sofia Wagemaker Viana , Anaís Concepcion Marinho Andrade de Moura MD , Beatriz Laus P. Lima , Niti Dalal MBBS MD , Aabha Divya MBBS, MCh
{"title":"Impact of severe obesity on heart transplantation outcomes: A meta-analysis of survival and complications","authors":"Ana Maria Bicudo Diniz MD , Adriana Loricchio Veiga MD , Sofia Wagemaker Viana , Anaís Concepcion Marinho Andrade de Moura MD , Beatriz Laus P. Lima , Niti Dalal MBBS MD , Aabha Divya MBBS, MCh","doi":"10.1016/j.jhlto.2025.100404","DOIUrl":"10.1016/j.jhlto.2025.100404","url":null,"abstract":"<div><h3>Background</h3><div>Heart transplantation (HT) is the standard treatment for end-stage heart failure, but severe obesity (Body Mass Index [BMI] ≥ 35 kg/m²) is linked to worse outcomes and is considered a relative contraindication. Obese patients face increased perioperative risks, longer wait times, and reduced survival, though improved clinical care may mitigate some effects. As obesity rates rise, the suitability of the current BMI is increasingly debated. Evidence remains limited and inconsistent, highlighting a need for clearer guidance. This systematic review and meta-analysis assess the impact of severe obesity on survival and post-transplant complications in HT recipients.</div></div><div><h3>Methods</h3><div>This systematic review and meta-analysis followed preferred reporting items for systematic reviews and meta-analyses (PRISMA) guidelines and was registered in PROSPERO (CRD420251036442). We included cohort studies and randomized controlled trials (RCTs) (2000–2025) comparing outcomes in adult heart transplant recipients with a BMI ≥ 35 kg/m² vs lower BMI. Primary outcomes were mortality and post-transplant complications. Searches were conducted in PubMed, Scopus, Embase, and Cochrane CENTRAL. Multiple reviewers did data extraction and bias assessment (ROBINS-I) independently. Random-effects models were used for statistical analysis, with heterogeneity assessed via I², and sensitivity analyses performed. Publication bias was evaluated using funnel plots.</div></div><div><h3>Results</h3><div>The search strategy retrieved 1,697 articles or abstracts, 595 were excluded for being duplicates, and 59 full-text articles were selected for full-text analysis. Of these, 9 cohorts were included, 7 from the United States and 2 from Canada, with 218,272 patients, of whom 206,459 had a BMI < 35 and 11,813 had a BMI ≥ 35kg/m².</div></div><div><h3>Conclusion</h3><div>This meta-analysis shows that severe obesity (BMI ≥ 35 kg/m²) remains associated with higher rates of infection, graft failure, and post-transplant mortality, despite advances in care. These outcomes likely reflect underlying immune and metabolic dysfunctions in obese patients, emphasizing the need for tailored strategies to improve long-term survival after heart transplantation.</div></div>","PeriodicalId":100741,"journal":{"name":"JHLT Open","volume":"11 ","pages":"Article 100404"},"PeriodicalIF":0.0,"publicationDate":"2026-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145521152","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}